Clinical therapeutics · 2025
Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Råket Hans Kristian, Milder Tamara, Litchfield Melisa, Jensen Camilla Bjørn, Wang Joanna Nan, Jimenez-Solem Espen, Petersen Janne, Pearson Sallie-Anne, Jaffe Adam, Falster Michael O
Аннотация
PURPOSE: Elexacaftor/tezacaftor/ivacaftor (ETI) is an efficacious targeted therapy for cystic fibrosis, but its impact on the use of maintenance therapies has not been assessed in Australia.
METHODS: We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression.
FINDINGS: Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable.
IMPLICATIONS: Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.
METHODS: We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression.
FINDINGS: Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable.
IMPLICATIONS: Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.
Предметные рубрики MeSH
Cystic FibrosisMaintenance ChemotherapyDrug CombinationsRetrospective StudiesAustraliaAnti-Bacterial AgentsGastrointestinal AgentsMolecular Targeted TherapyChloride Channel AgonistsFollow-Up StudiesHumansMaleFemaleAdolescentYoung AdultAdultDrug PrescriptionsQuinolinesPyrazolesBenzodioxolesIndolesPyridinesAminophenols